After reports of brain swelling (encephalitis and meningoencephalitis), the makers of Zinbryta®(daclizumab) have decided to withdraw it from the market.1
If you are taking Zinbryta, please call your program nurse.
Zinbryta was approved by the FDA (US Food and Drug Administration) in 2016 as an option for adults with relapsing multiple sclerosis. The drug carried a boxed warning about the risks of liver damage.
Zinbryta can still be used while its makers, Biogen Inc. and AbbVie, are working with the FDA on a withdrawal date. If you are taking Zinbryta, work with your doctor to explore other treatment options. CVS Health is also reaching out to doctors who have patients taking Zinbryta.
1 Biogen and AbbVie announce the voluntary worldwide withdrawal of marketing authorizations for Zinbryta® (daclizumab) for relapsing multiple sclerosis. BusinessWire website www.businesswire.com. Accessed March 2, 2018.